Informação da revista
Vol. 34. Núm. 9.
Páginas 569 (setembro 2015)
Partilhar
Partilhar
Baixar PDF
Mais opções do artigo
Vol. 34. Núm. 9.
Páginas 569 (setembro 2015)
Letter to the Editor
Open Access
Low-dose intravenous tissue-type plasminogen activator for prosthetic valve thrombosis is better than standard dose streptokinase
Baixas doses de activador de plasminogéneo tecidular intravenoso são preferíveis às doses estandardizadas para trombose de prótese valvular
Visitas
5284
Murat Bitekera, Özcan Başarana,
Autor para correspondência
basaran_ozcan@yahoo.com

Corresponding author.
, Nesrin Filiz Başaranb, Funda Sungur Bitekerc
a Muğla Sıtkı Koçman University, Faculty of Medicine, Department of Cardiology, Mugla, Turkey
b Muğla Sıtkı Koçman University, Faculty of Medicine, Department of Medical Pharmacology, Mugla, Turkey
c Muğla Sıtkı Koçman University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Mugla, Turkey
Este item recebeu

Under a Creative Commons license
Informação do artigo
Texto Completo
Bibliografia
Baixar PDF
Estatísticas
Texto Completo

We have recently read with great interest the article by Cardoso et al. entitled “Prosthetic mitral valve thrombosis in pregnancy: from thrombolysis to anticoagulation”.1

The authors reported a case of mitral prosthetic valve thrombosis (PVT) in early pregnancy, which was successfully treated with streptokinase. Streptokinase was administered using a loading dose of 250000 IU given over 30 min, followed by 100000 IU/h infusion. We congratulate the authors for their successful management strategy of such a high-risk patient, but we would like to comment on a few points of the authors’ paper.

PVT is an uncommon but serious complication of heart valve replacement procedures. Because of associated prothrombotic alterations, pregnancy in women with mechanical heart valves carries a high rate of PVT and thromboembolic complications.2–4 Özkan et al. recently published the results of the largest series of pregnant patients with PVT.5 This single-center, prospective, non-randomized, observational study included 24 consecutive pregnant women (25 pregnancies with 28 PVT episodes over an eight-year period) with left-sided PVT (all mitral; n=27). Patients with obstructive and nonobstructive PVT with recent systemic thromboembolism and a thrombus diameter of >5 mm and patients with asymptomatic mobile nonobstructive PVT with a thrombus diameter of at least 10 mm were included in the study. A specific thrombolytic protocol was used (25 mg tissue-type plasminogen activator infusion for six hours for each thrombolytic session, repeated once after 24 hours up to six times with a maximum total dose of 150 mg). They found a 100% thrombolytic success rate with no maternal mortality. Neonatal mortality in the series by Özkan et al. was 20%, similar to the incidence reported in other studies.

Despite the limitations of the study, this protocol seems to be an effective therapy with an excellent success rate for the treatment of PVT in pregnant women. It also seems to be safer than cardiac surgery or alternative medical strategies published to date. In conclusion, according to the current data, rather than standard dose streptokinase, low-dose, slow-infusion tissue-type plasminogen activator should be considered as the first-line therapy in pregnant patients with PVT.

References
[1]
G. Cardoso, C. Aguiar, M.J. Andrade, et al.
Prosthetic mitral valve thrombosis in pregnancy: from thrombolysis to anticoagulation.
Rev Port Cardiol, 34 (2015), pp. 71.e1-71.e5
[2]
M. Biteker, M. Ozkan.
Treatment of obstructive prosthetic heart valve thrombosis in pregnancy.
[3]
M. Ozkan, M. Biteker, A.E. Oğuz, et al.
Prosthetic mechanic valve thrombosis in pregnant women.
Turk Kardiyol Dern Ars, 37 (2009), pp. 215-217
[4]
M. Ozkan, M. Biteker, N.E. Duran, et al.
Images in cardiovascular medicine. Huge prosthetic mitral valve thrombosis in a pregnant woman.
Circulation, 120 (2009), pp. e151-e152
[5]
M. Özkan, B. Çakal, S. Karakoyun, et al.
Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue-type plasminogen activator.
Copyright © 2015. Sociedade Portuguesa de Cardiologia
Baixar PDF
Idiomas
Revista Portuguesa de Cardiologia
Opções de artigo
Ferramentas
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Ao assinalar que é «Profissional de Saúde», declara conhecer e aceitar que a responsável pelo tratamento dos dados pessoais dos utilizadores da página de internet da Revista Portuguesa de Cardiologia (RPC), é esta entidade, com sede no Campo Grande, n.º 28, 13.º, 1700-093 Lisboa, com os telefones 217 970 685 e 217 817 630, fax 217 931 095 e com o endereço de correio eletrónico revista@spc.pt. Declaro para todos os fins, que assumo inteira responsabilidade pela veracidade e exatidão da afirmação aqui fornecida.